Moderna's Cancer Vaccine Just Cleared a Real Phase 3 Bar
Moderna and Merck just put mRNA cancer treatment on the map in a way the market could not ignore.
On Wednesday, the partners said their personalized mRNA therapy, intismeran autogene, combined with Merck's Keytruda, met the main goals of a large Phase 3 melanoma trial. Patients who had high-risk skin cancer surgically removed saw better recurrence-free survival and better distant metastasis-free survival than Keytruda alone.
This is the first positive late-stage readout for an individualized mRNA cancer vaccine of this kind. That sentence alone is why the stock went vertical.
Why the market lost its mind
Moderna spent years being priced like a COVID company looking for a second act. A clean Phase 3 signal in adjuvant melanoma is a second act people can actually understand. The trial enrolled more than 1,100 patients. The therapy is built around each patient's tumor mutations, up to dozens of targets, then paired with a drug doctors already know.
Shares ripped on the news. There were triple-digit gains early in the day. The next day brought the hangover. Profit-taking hit hard after a move that size. That does not erase the science. It does remind you biotech still trades like a mood ring when the headline is this big.
As for me, the part I respect is simple. Cancer recurrence after surgery is a real fear families carry home from the hospital. If a customized shot on top of standard care can push that risk down in a serious trial, that is American biotech doing the job people actually care about.
What still has to go right
Regulators still have to dig through the full package. Manufacturing a personalized vaccine at scale is not a simple pill factory story. Pricing, timing, and how oncologists actually use this will decide whether the stock story becomes a product story.
Merck already owns the Keytruda franchise. Moderna needs this platform to look like more than one lucky melanoma win. Wall Street will try to package both sides of that trade before the dust settles.
Bottom line: Moderna just proved mRNA can matter in cancer in a late-stage trial, and the only honest follow-up is whether the company can turn a historic readout into a therapy patients can actually get.
Money Morning is not a registered investment advisor. This article is for informational purposes only and should not be construed as investment advice. Past performance is not indicative of future results. We may receive compensation for promoting third-party products and services. Always do your own due diligence before investing.